NCT06948786 2026-04-22Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialUniversity of WashingtonPhase 2 Recruiting22 enrolled
NCT06859008 2026-04-20Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical CenterPhase 1 Recruiting37 enrolled
NCT06191887 2026-02-13B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesMayo ClinicPhase 1 Recruiting27 enrolled
NCT06712810 2025-10-10Q702 for the Treatment of Patients With Hematologic MalignanciesMayo ClinicPhase 1 Recruiting46 enrolled